Revisiting Post-Prostatectomy Salvage Radiation in the Age of Precision Oncology
This activity covers updates and evolving data in treating biochemically recurrent prostate cancer post-prostatectomy. One speaker covers fractionation: can we safely hypofractionate in the post-operative setting, or is the data more supportive of conventional fractionation?
Category
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Androgen Deprivation Therapy and Dose Escalation for Prostate Cancer: Lessons from Randomized Trials and the MARCAP Consortium
Numerous randomized trials have studied the benefit of adding androgen deprivation therapy (ADT) and/or prolonging its duration when treating localized prostate cancer with radiotherapy, while other trials have interrogated the benefit of escalating radiotherapy dose itself.
Category
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Evolving Paradigms in Prostate Cancer: The Integral Role of PSMA PET/CT in Primary Staging and Therapeutic Decision-Making
The incidence of prostate cancer is increasing, with most diagnosed with localized disease. Appropriate staging is crucial to ensure optimal treatments are delivered.
Category
  • Genitourinary
Format
  • Journal Activities
Credits
  • 1.00 AMA PRA Category 1 Credit™
Cost $49.00
Radiation Therapy for Anal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline
This activity provides practitioners with the knowledge to recognize optimal RT management decisions for anal cancer.
Category
  • Genitourinary
Format
  • Journal Activities
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $49.00
Patient Reported Outcomes Following MR-guided Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis
In this activity participants will learn how MR-guided radiation therapy impacts patient-reported outcomes in patients with prostate cancer.
Category
  • Genitourinary
Format
  • Journal Activities
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $49.00
ROBIN Oligometastasis (OligoMET) Center: Using Biomarker Correlates from a Prostate Cancer Clinical Trial to Improve Future Outcomes
Metastasis is the final common lethal pathway for most cancer patient's demise and once cancer has metastasized, it was generally considered incurable.
Category
  • Genitourinary
  • Oligometastatic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Renal SABR: Implementation of A New Standard of Care
This paper, using a question and answer format, comprehensively explores and presents the data for SABR treatment of patient’s with RCC. The data and clinical care aspects of patient selection, radiotherapy treatment planning and delivery and post-treatment follow-up care are presented.
Category
  • Genitourinary
Format
  • Journal Activities
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $49.00
Practical Radiation Oncology Program 2025
This program is designed to address the needs of a community practice physician and includes disease site reviews, interactive case-based discussions, a strategic dialogue with the ASTRO CEO and a radiation oncology practice overview.
Category
  • Breast
  • Central Nervous System
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Head and Neck
  • Sarcoma
  • SBRT
  • Skin
  • Thoracic
Format
  • onDemand
Credits
  • 13.75 AMA PRA Category 1 Credit™
  • 13.75 Certificate of Attendance
Cost $849.00
ASTRO/KCA Joint Activity: Stereotactic Radiotherapy and Renal Cell Cancer, Overcoming Radioresistance and the Resistance to Radiate
This activity brings together an international panel and multidisciplinary expertise to discuss the emerging role of SABR to the primary in renal cell carcinoma (RCC).
Category
  • SBRT
  • Genitourinary
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Common Misinformation About Prostate Cancer and What To Do Webinar
Misinformation about prostate cancer is widespread in online networks and commonly raised during clinical encounters. Failing to address information can result in harms for patients, and challenging discussions about misinformation can lead to discord in the patient-clinician relationship.
Category
  • Genitourinary
Format
  • Upcoming Webinar
  • Webinars
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $49.00

Pages